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OBJECTIVES: The purpose of this study was to analyze the
impact of an inspector’s stamp approval policy into the atypical
antipsychotic market which was approved in 2003 in Andalusia–
Spanish Region- and in 2004 in the rest of Spain. METHODS:
The antipsychotic market in Spain, deﬁned as the number of
units sold, was described before and after the policy implemen-
tation (2003 and 2005). Data was collected from IMS database.
Chi-squared analysis was used to contrast the atypical anti-
psychotic market in Andalusia in contrast with the rest of Spain
before and after the policy implementation. Chi-squared analysis
was also used for each leading product in the market of the
atypical antipsychotics. Percentages of atypical and conventional
antipsychotic sales in Andalusia were also compared in contrast
with the rest of Spain for 2006 data. RESULTS: Sales
grew constantly from 1996—approval of the ﬁrst atypical
antipsychotics- to 2006—after the policy implementation-. The
patients treated with antipsychotics were mainly young adults,
with no differences in prescription by gender. Andalusian
sales proportion decreased for all main atypical anti-
psychotics—differences were signiﬁcant-. In Andalusia the per-
centage of atypical antipsychotic sales over the total
antipsychotics has also decreased since the policy was estab-
lished. Atypical antipsychotics sales were 25,7% less in Andalu-
sia than in the rest of Spain in 2006. Differences found for the
main atypical antipsychotics were 68.5% for Quetiapine, 52.3%
for Risperidone, 42.7% for Olanzapine and 25.2% for Sulpiride.
CONCLUSION: Despite the general market growth, the impact
of the inspector’s stamp approval contributed to a decrease in
atypical antipsychotic sales in Andalusia, meaning less pharma-
ceutical expenditure. It would be interesting to evaluate if, ratio-
nalising policies, apart from reducing the pharmaceutical
expenditure, may cause an impact in the Andalusian population
health.
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OBJECTIVES: To assess antipsychotic medication use, treatment
dynamics and associated patient symptomatology in a multi-
center setting in Spain, and generate annualized estimates at
country-level. METHODS: AntipsychosisMonitor is an annual
study conducted among psychiatrists in hospitals and private
practices to collect chart data on patients who were prescribed
any antipsychotic medication during the study window/
encounter. Diagnosis, treatment patterns/dynamics, side-effects
and patient symptomatology (cognition, positive & negative)
were assessed. Current analysis utilized 2006 data from 100
psychiatrists & 1900 patient charts. A multi-stage weighting
method at physician/patient level was employed to extrapolate
data to Spain population. RESULTS: Approximately 335,000
patients were estimated to have used antipsychotic medications
in 2006 (atypicals/typicals: 88%/16%; mono/dual/triple/
quadruple therapy: 43%/35%/20%/2%); Overall, patients had
the following diagnoses: schizophrenia (60%), bipolar-disorder
(15%), psychotic disorders (9%), dementias (8%), personality
disorder (7%) & mood disorder (2%). Cognitive, positive &
negative symptomatologies respectively in the entire cohort & in
the top-3 diagnostic groups were—all-patients: 80%, 70% &
61%, schizophrenia: 79%, 73% & 72%, bipolar-disorder: 80%,
56% & 33%, psychotic disorders: 72%, 77% & 48%. Anxi-
olytics (16%), antidepressants (14%) & mood stabilizers (11%)
were top-3 concomitant medications; atypical antipsychotic
use included: risperidone (31%), olanzapine (26%), quetiapine
(17%), aripiprazole (7%), amisulpride (6%), ziprasidone (5%)
& clozapine (4%). Approx. 15% of patients were new patients
requiring antipsychotic starts, whereas, majority of patients con-
tinued on previous regimen during the study encounter. Choice of
individual atypicals was inﬂuenced by positive symptomatology,
product efﬁcacy/safety & convenience/compliance. CONCLU-
SION: Less that two-third and one-half of the patients in Spain
using antipsychotics had schizophrenia and on monotherapy
respectively. Medication choice was driven by patient’s positive
symptomatology & product efﬁcacy/safety. Further research is
warranted to asses the impact of current antipsychotics treatment
patterns on clinical and economic outcomes in this population.
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OBJECTIVES: There are high rates of polypharmacy with antip-
sychotic medications. Antipsychotic drugs are mainly metabo-
lized by the cytochrome system; risperidone is primarily
metabolized by CYP3A4 and CYP2D6, quetiapine by CYP3A4,
and olanzapine by CYP1A2. There are many commonly used
medications that may inhibit or induce metabolism via these
enzyme systems. There is therefore a risk of drug-drug interac-
tions (DDIs) when these medications are taken concomitantly.
The objective of this study was to describe the rates of
co-medication with antipsychotics that may lead to DDIs in
Ontario, Canada. METHODS: A retrospective analysis of claims
data was conducted from March 2006–February 2007 using data
obtained from Brogan Inc. Inhibitors and inducers of the major
metabolic enzymes of risperidone (CYP2D6 and CYP3A4), que-
tiapine (CYP3A4) and olanzapine (CYP1A2) were identiﬁed
using published literature and drug information sources. The
prevalence of co-medication with risperidone, quetiapine and
olanzapine and respective inducers and inhibitors of CYP2D6
and CYP3A4, CYP3A4 alone and CYP1A2 alone was described.
RESULTS: A total of 57.5% of claims for risperidone overlapped
at least 25% with claims with one or more inhibitor or inducer
of CYP3A4 or 2D6. Similarly, 43.9% of quetiapine claims over-
lapped with one or more inhibitor/inducer of CYP3A4, and
24.0% of olanzapine claims for one or more inhibitor/inducer of
CYP1A2. The most commonly overlapping inhibitor/inducer
with risperidone were selective serotonin reuptake inhibitors
(SSRIs; 22.7% of claims). SSRIs that interacted with CYP1A2
were also the most commonly used co-medication with olanza-
pine (7.8%), while gastrointestinal acid suppression agents were
the most common inhibitor/inducer with quetiapine (9.7%).
CONCLUSION: A high percentage of Ontario drug beneﬁt
beneﬁciaries were prescribed both an atypical antipsychotic and
a medication that may interfere with its metabolism. This may
have implications for untoward clinical outcomes such as adverse
effects or exacerbation of illness.
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